Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast Insights: The Road To $62.12 Billion By 2030
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Duchenne Muscular Dystrophy (DMD) Therapeutics Market Poised To Hit $62.12 Billion By 2030 With A 30.5% CAGR
The duchenne muscular dystrophy (dmd) therapeutics market size has experienced significant expansion in recent years. It is anticipated to increase from $16.38 billion in 2025 to $21.43 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 30.8%. The historical growth in this sector is attributable to the rising prevalence of duchenne muscular dystrophy, enhanced awareness among healthcare providers, the initiation of early-stage clinical trials, broader adoption of physiotherapy and supportive care, and government incentives for rare disease treatments.
The duchenne muscular dystrophy (dmd) therapeutics market is anticipated to experience significant expansion in the upcoming years. It is projected to reach $62.13 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 30.5%. This growth over the forecast period is fueled by advancements in gene therapy, increasing investment in precision medicine, the integration of technology in patient monitoring, the scaling up of biologics manufacturing, and enhanced collaboration between pharmaceutical and biotech companies. Prominent trends for the forecast period include the development of personalized therapeutics, continued progress in gene editing and gene therapy, innovative drug delivery systems, the broadening of the orphan drug market, and the adoption of patient-centric care models.
Get A Free Sample Report With In-Depth Market Insights:
Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Backed By Core Demand Fundamentals
An increasing volume of clinical trials is anticipated to drive the expansion of the Duchenne muscular dystrophy (DMD) therapeutics market in the future. These trials involve research studies with human subjects, aiming to assess the safety, effectiveness, and prospective advantages of novel medical therapies, procedures, or pharmaceuticals. The surge in clinical trials is a result of the rising need for groundbreaking treatments that cater to existing medical gaps. Specifically, Duchenne muscular dystrophy (DMD) therapeutics undergo testing in these trials to determine their capacity to decelerate the disease’s progression and enhance patients’ muscle function. As an illustration, a report from April 2025 by the NLM (National Library of Medicine), a US government agency, indicated that 27,751 interventional clinical trials commenced in 2023. Consequently, the increasing initiation of clinical trials is set to boost the expansion of the Duchenne muscular dystrophy (DMD) therapeutics market.
Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment Outlook: Which Categories Are Growing Fastest?
The duchenne muscular dystrophy (dmd) therapeutics market covered in this report is segmented –
1) By Type: Small Molecules, Biologics
2) By Distribution Channel: Offline, Online
3) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Small Molecules: Exon Skipping Therapies, Antisense Oligonucleotides, Read-Through Compounds
2) By Biologics: Gene Therapies, Cell Therapies, Protein Replacement Therapies
Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Trends Reshaping The Competitive Landscape
Leading companies in the duchenne muscular dystrophy (DMD) therapeutics market are integrating novel technologies to boost the effectiveness and accessibility of treatments for DMD patients, thereby sustaining their market standing. For example, Bit Bio Ltd., a UK-based synthetic biology company, released disease model products in July 2023 to further Duchenne muscular dystrophy treatments. These disease models, identified as ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, consist of human skeletal myocytes with genetically engineered deletions in the gene that produces dystrophin protein. Bit. Bio’s models, which are reprogrammed from induced pluripotent stem cells (iPSCs), offer a consistent and scalable supply of human cells for research, thereby resolving issues linked to variability and the procurement of primary cells. The models aid in the advancement of DMD treatments, furnishing insights into disease mechanisms and prospective therapies. This breakthrough could hasten researchers’ pursuit of effective DMD treatments.
Duchenne Muscular Dystrophy (DMD) Therapeutics Market Leading Companies And Competitive Benchmarking
Major companies operating in the duchenne muscular dystrophy (dmd) therapeutics market are BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Exonics Therapeutics Inc., Wave Life Sciences Ltd., MeiraGTx Holdings plc, Editas Medicine Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc, CRISPR Therapeutics AG, Akouos Inc., Audentes Therapeutics Inc., Stoke Therapeutics Inc., Astellas Pharma Inc., Translate Bio Inc., Ultragenyx Pharmaceutical Inc.
View The Full Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report:
Duchenne Muscular Dystrophy (DMD) Therapeutics Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the DMD therapeutics market in 2025. The regions covered in the duchenne muscular dystrophy (dmd) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
